Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
brentuximab vedotin
Brentuximab vedotin is an IgG1 antibody-drug conjugate (ADC) specific for CD30 on the surface of several types of tumor cells, including Hodgkin's disease and some lymphomas. The complex is internalized and transported to lysosomes where the antitumor agent monomethyl auristatin E (MMAE) is released by proteolytic cleavage. MMAE binds to tubulin and disrupts the microtubule network in the cell.
Exposure is dose proportional, with no evidence of accumulation (q3w dosing). MMAE exposure falls with continued administration.
| Time to reach steady state |
21 days (q3w dosing) |
| Peak plasma levels | Tmax = 1-3 days for MMAE |
| PPB | 68-82%, MMAE is unlikely displace or to be displaced by highly protein-bound drugs |
Studies suggest that only a small fraction of MMAE released from brentuximab vedotin is metabolized.
| Main enzymes involved | CYP3A4/5 |
| Active metabolites |
Yes |
| Inhibitor of | CYP3A4/5 |
MMAE appears to follow metabolite kinetics, with elimination limited by its rate of release from ADC.
| Half-life |
4 to 6 days (3-4 for MMAE) |
| Feces | 72% (MMAE) |
| Urine | 28% (MMAE) |
- Hodgkin lymphoma (HL)
- Systemic anaplastic large cell lymphoma (sALCL)
- Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)
- Angioimmunoblastic T-Cell lymphoma (AITL)
- Primary cutaneous anaplastic large cell lymphoma (pcALCL)
- Mycosis fungoides (MF)
Refer to the product monograph for a full list and details of approved indications.
Emetogenic Potential:
Extravasation Potential: None
The following adverse effects include those reported in the placebo-controlled phase III trial in high risk HL patients following ASCT where the incidence was 2% or more higher than reported for placebo. Severe adverse effects from other trials are included, where appropriate.
| ORGAN SITE | SIDE EFFECT* (%) | ONSET** | |||
|---|---|---|---|---|---|
| Cardiovascular | Arrhythmia (<5%) (rare) | I E | |||
| Arterial thromboembolism (rare) | E | ||||
| Hypotension (6%) | I | ||||
| Venous thromboembolism (rare) | E | ||||
| Dermatological | Rash, pruritus (12%) | E | |||
| Stevens-Johnson syndrome (rare) | E | ||||
| Toxic epidermal necrolysis (rare) | E | ||||
| Gastrointestinal | Abdominal pain (14%) | E | |||
| Anorexia, weight loss (19%) | E | ||||
| Constipation (13%) | E | ||||
| Diarrhea (20%) | E | ||||
| Dyspepsia (7%) | I E | ||||
| GI obstruction (rare) | E | ||||
| GI perforation (rare) | E | ||||
| Nausea, vomiting (22%) | I E | ||||
| General | Fatigue (24%) | E | |||
| Hematological | Myelosuppression ± infection, bleeding (78%) (39% severe, including anemia, opportunistic infections) | E | |||
| Hepatobiliary | Hepatotoxicity (rare) | E D | |||
| ↑ LFTs (2%) (may be severe) | E | ||||
| Pancreatitis (rare) | D | ||||
| Hypersensitivity | Infusion related reaction (15%) (may be severe) | I E | |||
| Metabolic / Endocrine | Hyperglycemia (2%) | E | |||
| ↓ K (6%) | E | ||||
| Tumour lysis syndrome (rare) | E | ||||
| Musculoskeletal | Musculoskeletal pain (18%) | E | |||
| Nervous System | Headache (11%) | I E | |||
| Insomnia (8%) | E | ||||
| Leukoencephalopathy (PML - rare) | E | ||||
| Peripheral neuropathy (56%) (sensory); motor (23%); (up to 10% severe) | E D | ||||
| Renal | Renal failure (rare) | E D | |||
| Respiratory | Cough, dyspnea (21%) | E | |||
| Pneumonitis (rare) | E | ||||
* "Incidence" may refer to an absolute value or the higher value from a reported range.
"Rare"
may refer to events with < 1% incidence, reported in post-marketing, phase 1 studies,
isolated data or anecdotal
reports.
** I = immediate (onset in hours to days)
E = early (days to weeks)
D = delayed (weeks to months)
L = late (months to years)
The most common side effects for brentuximab vedotin include myelosuppression ± infection, bleeding, peripheral neuropathy, fatigue, nausea/vomiting, cough, dyspnea, diarrhea, anorexia, weight loss, musculoskeletal pain, infusion related reaction and abdominal pain.
Infections with brentuximab vedotin may be serious (e.g. pneumonia, bacteremia, herpes zoster) and/or opportunistic (e.g. pneumocystis jiroveci pneumonia, oral candidiasis). JC virus related progressive multifocal leukoencephalopathy (PML) has been reported, may be fatal and may be associated with immunosuppressive therapies and underlying disease. Some cases have occurred within 3 months of initial drug exposure. Patients should be closely monitored and the drug held with any sign or symptom suggestive of PML, while undergoing further evaluation.
Severe anemia, thrombocytopenia, and neutropenia (with or without fever) have been observed.
Severe rashes including Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been described and may be fatal.
Transient or persistent antibodies to brentuximab vedotin have been observed in up to 27% of patients and are associated with a higher risk of infusion reactions.
Infusion reactions can be immediate or delayed, may be severe and can occur up to 2 days after the infusion.
Peripheral neuropathy (PN) is cumulative and may be sensory or motor. It is often reversible after treatment ends, but may be severe or not completely reversible in some patients.
Non-infectious pulmonary toxicity, including cough, dyspnea, and interstitial infiltration and/or inflammation on imaging has been reported with single-agent brentuximab vedotin and may be fatal. The risk appears to be higher with bleomycin (contraindicated).
Consider pancreatitis (fatal cases reported) as a diagnosis in patients who present with new or worsening abdominal pain.
GI complications, including those with fatal outcomes, have been reported. Lymphoma patients with pre-existing GI involvement may have an increased risk of perforation.
Serious cases of hepatotoxicity have occurred, including deaths, after the first dose or re-challenge. Risk may be increased with pre-existing liver disease or elevated baseline liver enzymes.
Hyperglycemia has been reported in patients with an elevated body mass index (BMI) with or without a history of diabetes mellitus.
Tumour lysis syndrome has been reported. Patients at risk (rapidly proliferating tumours or high tumour burden) should have appropriate prophylaxis and be monitored closely.
Responses had been reported when patients who had prior responses to brentuximab vedotin were retreated. There was an increased incidence of neuropathy and upper respiratory tract infections with treatment beyond 16 cycles.
Refer to protocol by which patient is being treated.
Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the hepatitis B virus screening and management guideline.
Premedication (Prophylaxis for Infusion Reactions):
- Routine pre-medication is not recommended.
- May consider pre-medication with acetaminophen, H1-receptor antagonist and corticosteroid if an IR has occurred in the past.
Other Supportive Care:
- Primary G-CSF prophylaxis is recommended starting cycle 1 for patients on AVD+BREN or CHP+BREN.
- Antiviral and antibiotic prophylaxis post-ASCT should be followed per institutional guidelines.
- Patients at risk of tumour lysis syndrome should have appropriate prophylaxis and be monitored closely.
|
Indication |
Brentuximab Vedotin Dose* |
Frequency |
|
Previously untreated stage IV HL:
|
1.2 mg/kg |
Q2 weeks |
|
HL consolidation, Relapsed/refractory HL, Relapsed/refractory sALCL, pcALCL or CD-30-expressing MF:
Previously untreated sALCL, CD30-expressing PTCL-NOS, CD30-expressing AITL:
|
1.8 mg/kg | Q3 weeks^ |
*Maximum dose: 120 mg (for 1.2 mg/kg dose) or 180 mg (for 1.8 mg/kg dose) in patients > 100 kg.
^For ASCT consolidation, start within 4-6 weeks post-ASCT or upon ASCT recovery.
|
Toxicity |
Type / Grade |
Brentuximab Vedotin Dose (AVD+BREN) |
Brentuximab Vedotin Dose (CHP+BREN) |
Brentuximab Vedotin Dose (Monotherapy) |
|
Peripheral neuropathy
|
Grade 2 |
Reduce to 0.9 mg/kg q2w.^ |
Sensory neuropathy: No change. Motor neuropathy: Reduce to 1.2 mg/kg q3w.^ |
Hold until improvement to Grade 1 or baseline, then restart at 1.2 mg/kg q3w.^ |
|
Grade 3 |
Hold until ≤ Grade 2 then restart at 0.9 mg/kg q2w.^ Consider discontinuing if already at 0.9 mg/kg q2w.^ |
Sensory neuropathy: Reduce to 1.2 mg/kg q3w.^ Motor neuropathy: Discontinue. |
||
|
Grade 4 |
Discontinue. |
|||
|
Neutropenia
|
Grade 3 or 4 |
Continue with growth factors. |
Give growth factor prophylaxis for subsequent cycles in patients not on primary G-CSF prophylaxis. |
Hold until ≤ Grade 2. Consider growth factor support for subsequent cycles. |
|
Recurrent Grade 4 despite the use of growth factors |
Consider discontinuing, or reduce to 0.9 mg/kg q2w.^ |
Consider discontinuing, or reduce to 1.2 mg/kg q3w.^
|
Consider discontinuing, or reduce dose to 1.2 mg/kg q3w^ when recovered to ≤ Grade 2. |
|
|
Thrombocytopenia |
Grade 3 or 4 |
Monitor closely and consider platelet transfusions or dose delays. |
||
|
SJS, TEN |
Any |
Discontinue and manage appropriately. |
||
|
PML |
Suspected, any grade |
Hold and investigate; discontinue if confirmed. |
||
|
Pancreatitis |
Suspected, any grade |
Hold and investigate; discontinue if confirmed. |
||
|
Pulmonary symptoms |
Any grade |
Hold and investigate; consider discontinuing if pneumonitis confirmed. |
||
|
Tumour lysis syndrome |
Suspected, any grade |
Hold and manage aggressively. May continue therapy after resolution with adequate preventative measures. |
||
|
Hepatotoxicity |
New, worsening or recurrent |
Hold and consider reduced dose. Discontinue if severe. |
||
^Maximum dose: 90 mg (for 0.9 mg/kg dose) or 120 mg (for 1.2 mg/kg dose) in patients ≥ 100 kg.
Management of Infusion-related Reactions:
Also refer to the CCO guideline for detailed description of Management of Cancer Medication-Related Infusion Reactions.
| Grade | Management | Re-challenge |
| 1 or 2 |
Restart:
|
|
| 3 |
Restart:
|
|
| 4 |
|
|
The liver is a known route of clearance for brentuximab vedotin. MMAE exposure approximately doubled in patients with hepatic impairment; a reduced starting dose should be used.
| Hepatic Impairment |
Dose (In Combination with AVD) |
Dose (Monotherapy or in Combination with CHP) |
| Mild (Child-Pugh A) | Start at 0.9 mg/kg† and monitor closely. | Start at 1.2 mg/kg† and monitor closely. |
| Moderate (Child-Pugh B) | Avoid use. | |
| Severe (Child-Pugh C) | Avoid use. | |
†Maximum dose: 90 mg (for 0.9 mg/kg dose) or 120 mg (for 1.2 mg/kg dose)in patients ≥ 100 kg.
No dose adjustment for mild or moderate renal impairment. Avoid use in patients with severe renal impairment (CrCl <30mL/min). The kidneys are a known route of clearance for brentuximab vedotin. MMAE exposure approximately doubled and severe adverse effects were more frequent in patients with severe renal impairment.
No specific dose adjustment is recommended by the manufacturer.
No meaningful safety or efficacy difference was observed between patients ≥ 65 years compared to younger patients with pcALCL or CD30-expressing MF.
Efficacy and safety of monotherapy have not been established in geriatric patients with HL at high risk of relapse, relapsed/refractory HL or relapsed/refractory sALCL.
Older age was a risk factor for febrile neutropenia in AVD+BREN and CHP+BREN clinical trials. Patients ≥ 65 years of age had higher incidences of ≥ Grade 3 and serious adverse effects compared with younger patients on CHP+BREN.
Females have been found to have a lower antibody-drug conjugate volume of distribution than males. Dosage adjustment is not needed.
- DO NOT administer as an IV push or bolus.
- Reconstitute based on product monograph instructions to yield a single-use 5 mg/mL solution.
- After reconstitution, immediately add to an infusion bag containing at least 100 mL volume to achieve a final concentration of 0.4-1.8 mg/mL.
- Can be diluted into normal saline, 5% dextrose or lactated Ringer's injection.
- Infuse IV over 30 minutes.
- Do not mix with, or administer as an infusion with, other medicinal products.
- Store unopened vials at 2-8°C in the original carton to protect from light.
Also refer to the CCO guideline for detailed description of Management of Cancer Medication-Related Infusion Reactions.
- Patients who are hypersensitive to this drug or any of its components
- Concomitant use with bleomycin due to increased risk of pulmonary toxicity
- Patients who have, or have had progressive multifocal leukoencephalopathy (PML)
- Patients with significant pre-existing cardiovascular disease should be monitored closely as the potential cardiotoxicity of brentuximab vedotin is unknown.
- Patients with baseline neuropathy, including asymptomatic Grade 1 neuropathy, were excluded from the AVD+BREN clinical trial. Benefit-risk must be carefully considered before starting AVD+BREN for previously untreated patients with stage IV HL who have pre-existing neuropathy.
- Use live vaccines with caution.
Other Drug Properties:
-
Carcinogenicity:
Unknown
-
Genotoxicity:
Yes
-
Crosses placental barrier:
Documented in animals
-
Fetotoxicity:
Documented in animals
-
Teratogenicity:
Documented in animals
-
Pregnancy:
Brentuximab is not recommended for use in pregnancy. Adequate contraception (including a barrier method) should be used by patients and their partners during treatment, and for at least 6 months after the last dose.
-
Excretion into breast milk:
Unknown
Breastfeeding is not recommended.
-
Fertility effects:
Probable
Documented in animal studies. Partially reversible in male animals.
MMAE is a P-gp and CYP3A4/5 substrate. Although MMAE is an in vitro inhibitor of CYP3A4/5, it is not expected to change the exposure to drugs that are metabolized by CYP3A4.
| AGENT | EFFECT | MECHANISM | MANAGEMENT |
|---|---|---|---|
| CYP3A4 inducers (i.e. phenytoin, rifampin, dexamethasone, carbamazepine, phenobarbital, St. John’s Wort, etc) | ↓ exposure to MMAE (up to 46%) | ↑ metabolism of MMAE | Caution; monitor for efficacy. |
| CYP3A4 inhibitors (i.e. ketoconazole, clarithromycin, ritonavir, fruit or juice from grapefruit, Seville oranges or starfruit) | ↑ exposure to MMAE (up to 34%) | ↓ metabolism of MMAE | Caution with strong inhibitors; monitor for adverse reactions closely. |
| P-glycoprotein inhibitors (i.e. quinidine, verapamil, cyclosporine) | ↑ exposure to MMAE | MMAE is a P-gp substrate | Caution; monitor for adverse reactions closely. |
| Bleomycin | ↑ risk of pulmonary toxicity | Unknown mechanism | CONTRAINDICATED. |
Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.
Refer to the hepatitis B virus screening and management guideline for monitoring during and after treatment.
| Monitor Type | Monitor Frequency |
|---|---|
| CBC | Baseline and prior to each dose; more frequent monitoring should be considered for patients with Grade 3 or 4 neutropenia or thrombocytopenia |
| Liver function tests | Baseline and before each cycle, also as clinically indicated in patients with liver impairment |
| Renal function tests | Baseline and before each cycle, also as clinically indicated in patients with renal impairment |
Clinical toxicity assessment for TLS, PML, infusion-related reactions, infections, bleeding, neuropathy, pneumonitis, pancreatitis, thromboembolism, GI or skin effects, fatigue, pain |
At each visit |
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
| Monitor Type | Monitor Frequency |
|---|---|
Blood glucose |
Baseline and as clinically indicated, especially for patients with a history of diabetes mellitus |
New Drug Funding Program (NDFP Website )
- Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
- Brentuximab Vedotin - Consolidation Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma
- Brentuximab Vedotin - Relapsed or Refractory Hodgkin Lymphoma
- Brentuximab Vedotin - Systemic Anaplastic Large Cell Lymphoma
- Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Stage IV Hodgkin Lymphoma
- Brentuximab Vedotin - Previously Treated Primary Cutaneous Anaplastic Large Cell Lymphoma or Mycosis Fungoides
Adis Data Information. Brentuximab vedotin. Drugs R D 2011;11(1):85-95.
Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res 2012;19(1):22-27.
Minich SS. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother 2012;46:377-83.
Product Monograph: Adcetris® (brentuximab vedotin). Seattle Genetics, Inc., June 2021.
Prescribing Information: Adcetris® (brentuximab vedotin). Seattle Genetics, Inc. January 2012.
Younes A, Yasotham U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov 2012;11:19-20.
September 2024 Updated Pregnancy and Lactation section
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.